 Dosing with TAK-831 will progress into study part 2 and 3, only after review of all available safety, tolerability, and PK data collected in Cohorts 1 to 2 of the Study Part 1 This single center trial will be conducted in the United Kingdom. The overall time to participate in this study is approximately up to 58 days. Participants will be admitted in the clinic for the up to 20 days, and will be contacted by telephone 14 days after last dose of study drug for a follow-up assessment. 